ULCERATIVE-NECROTIZING ANGIITIS ON A BACKGROUND OF RECEPTION OF LENVATINIB IN THYROID CANCER


Cite item

Full Text

Abstract

The information about modern targeted drugs used in chemotherapy regimens for different types of cancer is presented. The mechanisms of pathogenesis of the development of undesirable skin reactions in the presence of tyrosine kinase receptor inhibitors are described. The clinical case of a rarely occurring reaction to drugs inhibitors of vascular growth factor in the form of ulcerative-necrotic skin lesions in a 63-year-old patient is presented.

About the authors

Ekaterina V. Orlova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: orlovaderm@yandex.ru
MD, PhD, docent of the Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119435, Russian Federation 119435, Moscow, Russian Federation

O. V Grabovskaya

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

L. M Smirnova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

L. A Shestakova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

N. I Melikova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

L. N Kayumova

Department of skin and venereal diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University)

119435, Moscow, Russian Federation

References

  1. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 2006; 91(8): 2892-9.
  2. Sgouros G., Kolbert K.S., Sheikh A., Pentlow K.S., Mun E.F., Barth A., et al. Patient-specific dosimetry for I131 thyroid cancer therapy using I124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J. Nucl. Med. 2004; 45(8): 1366-72.
  3. Каприн А.Д., Старинский В.В., Петров Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИЦ радиологии Минздрава России; 2018. http://www.oncology.ru/service/statistics; https://www.rakfond.org/2018/10/19/cancer-statistics-incidence-and-mortality_ru/
  4. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998; 83(12): 2638-48.
  5. Sciuto R., Romano L., Rea S., Marandino F., Sperduti I., Maini C.L. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann. Oncol. 2009; 20(10): 1728-35.
  6. Pacini F., Castagna M.G. Approach to and treatment of differentiated thyroid carcinoma. Med. Clin. North Am. 2012; 96(2): 369-83.
  7. Xing M., Haugen B., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381(9871): 1058-69.
  8. Amin A., Badwey A., El-Fatah S. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin. Nucl. Med. 2014; 39(2): 142-6.
  9. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000; 289(5483): 1357-60.
  10. Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol. Cell Endocrinol. 2010; 321(1): 20-8.
  11. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003; 284(1): 99-110.
  12. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008; 14(17): 5459-65.
  13. Grande E., Diez J.J., Zafon C., Capdevila J. Thyroid cancer: molecular aspects and new therapeutic strategies. J. Thyroid. Res. 2012; 2012: 847108.

Copyright (c) 2019 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies